Pharma Focus Asia

PCI Pharma Services Invests US$100 million to Expand Manufacturing Capacity

PCI Pharma Services plans for the expansion of manufacturing facility with the addition of world-class facilities. The facility will be located at Bedford, USA.

The new manufacturing facility will be constructed with an area covering 50,000 square foot to increase breadth of services as a global CDMO. It helps in providing high-volume lyophilisation, liquid filling, and multi-product handling from one format to another.

The facility consists of state of the art technology, along with aseptic fill-finish line accomplished with a fully isolated containment system. In addition, the facility is also equipped with twin lyophilisers with both auto-loading and unloading systems having the capacity to complete 400 vials per minute on a sterile fill-finish line, allowing to reach market faster and helping these therapies to reach patients earlier.

The expansion enhances the capabilities and capacity in aseptic liquid fill-finish and sterile lyophilisation technology, the most important manufacturing process commonly used with injectable and biologic therapies.


NamePCI Pharma Services
TypeNew Construction
BudgetUS$100 million
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?